Navigation Links
Celladon Corporation Announces Publication of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
Date:9/26/2013

SAN DIEGO, Sept. 26, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced the full three year long-term follow up results from Phase 2a of the CUPID 1 trial in the online publication of Circulation Research. Phase 2a of the CUPID 1 trial investigated Celladon's product candidate MYDICAR in three dose groups for the treatment of advanced heart failure.

"The long term trends observed in the full three years of follow up from the CUPID 1 trial in the MYDICAR high dose group are very encouraging," said Krisztina Zsebo, Ph.D., President and Chief Executive Officer of Celladon Corporation. "The duration of clinical response in the high dose group, coupled with the favorable trend in mortality and lack of safety concerns, leaves us optimistic for future development of MYDICAR."

In the additional two year follow up period of the CUPID 1 trial, the durability of reduced cardiovascular and terminal events previously observed in the MYDICAR high dose cohort at 12 months was maintained. The following recurrent cardiovascular and terminal events were tracked over the three years in all MYDICAR dose groups: myocardial infarction, worsening heart failure, heart failure-related hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause death. The risk of pre-specified recurrent cardiovascular events through full three years of follow up was reduced by 82% in the high dose group compared to the placebo group (p=0.048, where p-value is the statistical probability of a result due to chance alone).

In addition, the survival probability over time was higher for patients in all MYDICAR dose groups compared to the placebo group, especially in the high dose group. At three years post-administration, there we
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
2. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
5. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
6. Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
9. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
10. Neogen Corporation Announces 2nd Quarter Results Conference Call
11. Luminex Corporation to Present at JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... been honored for its commitment to sustainability with inclusion on ... is the highest ranked healthcare equipment company among the Corporate ... the World Economic Forum at Davos, Switzerland ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... DIEGO, June 8 , , WHO: ... and panelists discussing life sciences and the business relationships between California ... , CALAsia is an international 2-day forum that will bring ... Asia Pacific region to identify, explore, and further trans-Pacific business endeavors. ...
... International, a leader in enabling and accelerating the global ... today announced a strategic drug co-development partnership with the ... of therapeutic areas and represents one of the first ... company and a Chinese university. , , HUYA ...
... June 8 CSL Limited (ASX: CSL) and Talecris Biotherapeutics, ... their merger agreement, announced on August 12, 2008, under which ... , , Dr. Brian McNamee, CEO and Managing Director ... Federal Trade Commission (FTC) resolved to block the transaction. ...
Cached Biology Technology:BIOCOM's Inaugural CALAsia Forum 'Bridging the Pacific' 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 2HUYA Bioscience Announces Strategic Collaboration With the Shenyang Pharmaceutical University 3CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 2CSL Limited and Talecris Biotherapeutics Agree to Terminate Merger Agreement 3
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... 15, 2014 The Defense Logistics Agency is insourcing ... prevent counterfeit microcircuits from entering into its supply chain. ... microcircuit anti-counterfeit initiative dubbed DNA marking. The capability will ... reliability throughout the supply chain. The new quality control ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... metabolic symptoms of 11 patients with a rare but ... (MSUD), according to a study by researchers from Children's ... , All patients from the study (ranging in age ... function, according to the researchers. Amino acid levels in ...
... A major conservation effort, led by Dr Brendan Godley ... to help protect endangered leatherback turtles which nest in ... the animals' last global stronghold, as pacific populations dwindle ... track the animals, will uncover their migratory secrets and ...
... Research Consortium scientists from The Walter and Eliza Hall ... stem cell that drives the formation of all breast ... how normal breast tissue develops. The identification of the ... about how breast cancer develops and how rogue cells ...
Cached Biology News:Pennsylvania researchers find liver transplants provide metabolic cure for rare genetic disease 2Scientist warns of threat to last stronghold of endangered turtle 2Faults in newly discovered breast stem cells may lead to tumours 2
Cell Culture Flask, 175 cm, tissue-culture treated polystyrene, barcoded...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... acquisition, analysis and experiment control software. ... with on-line and off-line analysis. powerful ... script language allowing the user to ... requirements. Applications range from basic data ...
... is a direct antibiotic-based ... identification. Recombinant selection depends ... eliminating the need for ... quick and inexpensive process ...
Biology Products: